A Pilot Study of Lenalidomide Alternating With Ipilimumab Post Allogeneic and Autologous Stem Cell Transplantation
Phase of Trial: Phase II
Latest Information Update: 21 Aug 2019
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; Lenalidomide (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Hodgkin's disease; Mantle-cell lymphoma
- Focus Adverse reactions
- 16 Aug 2019 Planned End Date changed from 30 Nov 2020 to 30 Nov 2019.
- 23 May 2019 Planned End Date changed from 1 Nov 2019 to 30 Nov 2020.
- 23 May 2019 Planned primary completion date changed from 1 Nov 2019 to 30 Nov 2019.